Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B.N., Kennedy, S.H., McIntyre, R.S., Milev, R.V., Parikh, S.V., Schaffer, A., Taylor, V.H., Tourjman, V., van Ameringen, M., Yatham, L.N., Ravindran, A.V. and Lam, R.W. (2020) The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 66, 113-125.
https://doi.org/10.1177/0706743720970860

has been cited by the following article:

• TITLE: Virtual Reality as an Adjunct to Ketamine Infusion Therapy Increases Patient Satisfaction in the Management of Chronic Pain and Depression: A Retrospective Pilot Study

  AUTHORS: Melissa C. Selinger, David M. Compton, Hamilton Morris, Timothy J. Canty

  KEYWORDS: Ketamine, Infusion Therapy, Virtual Reality, Chronic Pain, Depression

  JOURNAL NAME: Journal of Behavioral and Brain Science, Vol.13 No.12, December 28, 2023

  ABSTRACT: The management of patients with concomitant chronic pain (CP) and Major Depressive Disorder (MDD) remains challenging for clinicians. Current chronic pharmacologic management is often unsuccessful, or has intolerable side effects to the patients. While not restricted to patients with chronic pain, these patients are often diagnosed with depression, presenting with symptoms such as poor mood, anhedonia, and altered cognitive processes. It is estimated that a substantial proportion of treated patients do not derive a substantive benefit from traditional pharmacological treatments for depression. The present study involved a retrospective review of cases, exploring the patient-reported satisfaction with and tolerability of a novel use of virtual reality (VR), coined KVR, as an adjunct to intravenous ketamine infusion therapies. Specifically, the ketamine-virtual reality protocol was employed as a potential adjunctive intervention for patients suffering from chronic pain and depression. Visual Analog Scores (VAS) associated with pain were significantly lower on the third than on the first assessment day. Montgomery-Åsberg Depression Rating Scale (MADRS) scores improved following infusion and across days (i.e., sessions). Lastly, 2/3 of patients preferred the use of VR with their ketamine infusion. The results are considered in terms of implementing prospective studies to examine whether the combination therapies have a synergistic benefit and the nature and magnitude of clinically meaningful treatment effects, if any.